DrugDashboards

PredniSONE Intensol

PredniSONE Intensol · PREDNISONE 5 mg/mL · Solution, Concentrate · Oral · Hikma Pharmaceuticals USA Inc.

NDC 00054-3721-44 · 30 mL in 1 BOTTLE, GLASS · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $3.14 per mL over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$3.14per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.0040per billing unit (1 MG)HCPCS J7512 · Jul 1, 2026
  • Part D plans paid (avg)$3.45per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$4.09per unitnegotiated price across 4,560 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$4.09per unit
middle half $3.41$4.34 · 4,560 plans · Apr 1, 2026
Est. net of rebates
≈ $4.09
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
83%of plans cover it
tier 4 · prior auth 51% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00Mar 2015Sep 2026$3.14
32 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$130.00
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.004
HCPCS J7512 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$222,899
1,280 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for prednisone intensol (other) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA088810
TE code
Approval date
Feb 20, 1985
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedOct 3, 2016
    West-Ward PharmaceuticalFailed Tablet/Capsule Specifications: Discovery of an underweight tablet.
  • Class III · TerminatedJun 14, 2013
    Boehringer Ingelheim Roxane IncLabeling: Missing Label; missing label on blister card

Manufacturers of PredniSONE Intensol (Solution, Concentrate)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.PREDNISONE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "PredniSONE Intensol — NDC 00054-3721-44," retrieved September 3, 2026, https://drugdashboards.com/drug/00054372144.

Free to cite with attribution — see how the data is put together.